PDIA6

Across TCGA pan-cancer cohorts, PDIA6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDIA6 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDIA6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDIA6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where PDIA6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.326	0.806	<.001	33	view →
LSCC	DFS	Median	II,III,IV	0.648	0.932	.001	20	view →
LUAD	OS	Median	II,III,IV	0.899	0.446	.018	6	view →
GBM	DFS	Median	All	0.256	0.480	.001	4	view →
HNSC	DFS	Quartile	III,IV	1.000	0.374	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDIA6–CCRCC (DFS)

Open the CCRCC breakdown →